Impaired vascular function in small resistance arteries of LOX-1 overexpressing mice on high-fat diet

Cardiovascular Research

Volumn 82, Issue 3, 2009, Pages 493-502

  Eichhorn, Birgit ^a   Muller, Gregor ^a   Leuner, Anja ^a   Sawamura, Tatsuya ^b   Ravens, Ursula ^a   Morawietz, Henning ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Endothelial function; K+ channel; Lectin like oxidized low density lipoprotein receptor 1 (LOX 1); Lipoproteins; Smooth muscle

Indexed keywords

CALCIUM ACTIVATED POTASSIUM CHANNEL; CYTOCHROME P450; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; LIPID; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL FUNCTION; BODY WEIGHT; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; LIPID BLOOD LEVEL; LIPID DIET; MALE; MESENTERIC ARTERY; MOUSE; MYOGRAPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE RELAXATION; VASCULAR SMOOTH MUSCLE; VOLTAGE CLAMP;

ANIMALS; BODY WEIGHT; CATTLE; DIET, ATHEROGENIC; DIETARY FATS; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; LIPIDS; MALE; MESENTERIC ARTERIES; MICE; MICE, INBRED C57BL; NITRIC OXIDE SYNTHASE TYPE III; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; SCAVENGER RECEPTORS, CLASS E; VASCULAR RESISTANCE;

EID: 66249130994     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp089     Document Type: Article

References (62)

1. Simionescu M. Implications of early structural-functional changes in the endothelium for vascular disease. Arterioscler Thromb Vase Biol 2007; 27:266-274.
2. Brevetti G, Schiano V, Chiariello M. Endothelial dysfunction: a key to the pathophysiology and natural history of peripheral arterial disease? Atherosclerosis 2008;197:1-11.
3. Doan AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vase Biol 2008;28:812-819.
4. Abularrage CJ, Sidawy AN, Aidinian G, Singh N, Weiswasser JM, Arora S. Evaluation of the microcirculation in vascular disease. J Vase Surg 2005;42:574-581.
5. Vohra RS, Murphy JE, Walker JH, Ponnambalam S, Homer-Vanniasinkam S. Atherosclerosis and the Lectin-like oxidized low-density lipoprotein scavenger receptor. Trends Cardiovasc Med 2006;16:60-64.
6. Chen XP, Zhang TT, Du GH. Lectin-like oxidized low-density lipoprotein receptor-1, a new promising target for the therapy of atherosclerosis? Cardiovasc Drug Rev 2007;25:146-161.
7. Morawietz H. LOX-1 and atherosclerosis: proof of concept in LOX-1 -knockout mice. Circ Res 2007;100:1534-1536.
8. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Yet al. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997;386:73-77.
9. Draude G, Hrboticky N, Lorenz RL The expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) on human vascular smooth muscle cells and monocytes and its down-regulation by lovastatin. Biochem Pharmacol 1999;75:383-386.
10. Mehta JL, Chen J, Hermonat PL, Romeo F, Novelli G. Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res 2006;69: 36-45.
11. Tatsuguchi M, Furutani M, Hinagata J, Tanaka T, Furutani Y, Imamura S et al. Oxidized LDL receptor gene (OLR1) is associated with the risk of myocardial infarction. Biochem Biophys Res Commun 2003;303:247-250.
12. Hattori H, Sonoda A, Sato H, Ito D, Tanahashi N, Murata M et al. G501C polymorphism of oxidized LDL receptor gene (OLR1) and ischemic stroke. Brain Res 2006;1121:246-249.
13. Kataoka H, Kume N, Miyamoto S, Minami M, Moriwaki H, Murase T et al. Expression of the lectin like oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation 1999;99:3110-3117.
14. Inoue K, Arai Y, Kurihara H, Kita T, Sawamura T. Overexpression of lectin-like oxidized low-density lipoprotein receptor-1 induces intramyocardial vasculopathy in apolipoprotein E-null mice. Circ Res 2005;97:176- 184.
15. + channels by oxidized LDL and its contribution to endothelial proliferation. Cardiovasc Res 2003;60:626-634.
16. Busse R, Fleming I. Vascular endothelium and blood flow. Handb Exp Pharmacol 2006;176:43-78.
17. Landmesser U, Drexler H. Endothelial function and hypertension. Curr Opin Cardiol 2007;4:316-320.
18. Brandes RP, Behra A, Lebherz C, Böger RH, Bode-Böger SM, Phivthong-Ngam L et al. N(G)-nitro-L-arginine- indomethacin-resistant endothelium-dependent relaxation in the rabbit renal artery: effect of hypercholesterolemia. Atherosclerosis 1997;135:49-55.
19. Honda H, Moroe H, Fujii H, Arai K, Notoya Y, Kogo H. Short term hypercholesterolemia alters N(G)-nitro-L-arginine and indomethacin-resistant endothelium relaxation by acetylcholine in rabbit renal artery. Jpn J Pharmacol 2001;85:203-206.
20. Kbhler R, Hoyer J. The endothelium-derived hyperpolarizing factor: insights from genetic animal models. Kidney Int 2007;72:145-150.
21. Feletou M, Vanhoutte PM. Endothelium-derived hyperpolarizing factor: where are we now? Arterioscler Thromb Vasc Biol 2006;26:1215-1225.
22. Michaelis UR, Fleming I. From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: Epoxyeicosatrienoic acids (EETs) and cell signaling. Pharmacol Ther 2006;111:584-595.
23. Tanaka Y, Koike K, Toro L. MaxiK channels roles in blood vessel relaxation induced by endothelium-derived relaxing factors and their molecular mechanisms. J Smooth Muscle Res 2004;40:125-153.
24. MunzelT, Afanas'ev IB, Kleschyov AL, Harrison DG. Detection of superoxide in vascular tissue. Arterioscler Thromb Vasc Biol 2002;22:1761- 1768.
25. Bolann BJ, Ulvik RJ. Release of iron from ferritin by xanthine oxidase. Role of the superoxide radical. Biochem J 1987;243:55-59.
26. Neidhold S, Eichhorn B, Kasper M, Ravens U, Kaumann AJ. The function of alpha- and beta-adrenoceptors of the saphenous artery in caveolin-1 knockout and wild-type mice. Br J Pharmacol 2007; 150:261-270.
27. Wuest M, Eichhorn B, Braeter M, Strugala G, Michel MC, Ravens U. Muscarinic receptor expression and receptor-mediated detrusor contraction: comparison of juvenile and adult porcine tissue. Pflugers Arch 2008; 456:349-358.
28. Jiang B, Wu L, Wang R. Sulphonylureas induced vasorelaxation of mouse arteries. Eur J Pharmacol 2007;577:124-128.
29. Matsumoto T, Kakami M, Kobayashi T, Kamata K. Gender differences in vascular reactivity to endothelin-1 (1-31) in mesenteric arteries from diabetic mice. Peptides 2008;29:1338-1346.
30. Busse R, Edwards G, Félétou M, Fleming I, Vanhoutte PM, Weston AH. EDHF: bringing the concepts together. Trends Pharmacol Sci 2002;23: 374-380.
31. Campbell WB, Falck JR. Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors. Hypertension 2007;49:590-596.
32. Shimokawa H, Matoba T. Hydrogen peroxide as an endothelium-derived hyperpolarizing factor. Pharmacol Res 2004;49:543-549.
33. + current in vascular endothelial cells. Cardiovasc Res 2000;4:1035-1045.
34. +channels. Mol Pharmacol 2007;72: 1033-1044.
35. Libinaki R, Heffernan M, Jiang WJ, Ogru E, Ignjatovic V, Gianello R et al. Effects of genetic and diet-induced obesity on lipid metabolism. IUBMB Life 1999;48:109-113.
36. Gallou-Kabani C, Vigé A, Gross MS, Rabès JP, Boileau C, Larue-Achagiotis C et al. C57BL/6J and A/J mice fed a high-fat diet delineate components of metabolic syndrome. Obesity 2007;15:1996- 2005.
37. Cannon CP. High-density lipoprotein cholesterol and residual cardiometa-bolic risk in metabolic syndrome. Clin Cornerstone 2007;8:14-12.
38. Xie H, Bevan JA. Oxidized low-density lipoprotein enhances myogenic tone in the rabbit posterior cerebral artery through the release of endothelin-1. Stroke 1999;30:2423-2429.
39. Galle J, Mameghani A, Bolz SS, Gambaryan S, Görg M, Quaschning T et al. Oxidized LDL and its compound lysophosphatidylcholine potentiate AngII-induced vasoconstriction by stimulation of RhoA. J Am Soc Nephrol 2003;14:1471-1479.
40. Ge ZD, Zhang XH, Fung PC, He GW. Endothelium-dependent hyperpolar-ization and relaxation resistance to N(G)-nitro-L-arginine and indometha-cin in coronary circulation. Cardiovasc Res 2000;46:547-556.
41. Huang A, Sun D, Smith CJ, Connetta JA, Shesely EG, Koller A et al. In eNOS knockout mice skeletal muscle arteriolar dilation to acetylcholine is mediated by EDHF. Am J Physiol Heart Circ Physiol 2000;278:762- 768.
42. Freiman PC, Mitchell GG, Heistad DD, Armstrong ML, Harrison DG. Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates. Circ Res 1986;58:783-789.
43. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990;344:160-162.
44. Golino P, Piscione F, Willerson JT, Cappelli-Bigazzi M, Focaccio A, Villari B et al. Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med 1991;324:641-648.
45. -2. implications for the action of endothelium-derived relaxing factor (EDRF). Free Radic Res Commun 1990;10:221-226.
46. Huie RE, Padmaja S. The reaction of no with superoxide. Free Radic Res Commun 1993;18:195-199.
47. Rueckschloss U, Galle J, Holtz J, Zerkowski HR, Morawietz H. Induction of NAD(P)H-oxidases by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation 2001;104:1767-1772.
48. Stielow C, Catar RA, Muller G, Wingler K, Scheurer P, Schmidt HH et al. Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells. Biochem Biophys Res Commun 2006;344: 200-205.
49. Lehoux S. Redox signalling in vascular responses to shear and stretch. Cardiovasc Res 2006;71:269-279.
50. Wareing M, Bai X, Seghier F, Turner CM, Greenwood SL, Baker PN et al. Expression and function of potassium channels in the human placental vasculature. Am J Physiol Regul Integr Comp Physiol 2006;291:437- 446.
51. Sandow SL, Tare M, Coleman HA, Hill CE, Parkington HC. Involvement of myoendothelial gap junctions in the action of endothelium-derived hyperpolarizing factor. Circ Res 2002;90:1108-1113.
52. Dora KA, Sandow SL, Gallagher NT, Takano H, Rummery NM, Hill C et al. Myoendothelial gap junctions may provide the pathway for EDHF in mouse mesenteric artery. J Vasc Res 2003;40:480-490.
53. Haddy FJ, Vanhoutte PM, Félétou M. Role of potassium in regulating blood flow and blood pressure. Am J Physiol 2005;290:R546-R552.
54. + channels. Cardiovasc Res 1998;37:780-790.
55. Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 1995;268:799-822.
56. Larsen BT, Gutterman DD, Sato A, Toyama K, Campbell WB, Zeldin DC et al. Hydrogen peroxide inhibits cytochrome P450 epoxygenases: interaction between two endothelium-derived hyperpolarizing factors. Circ Res 2008;102:59-67.
57. Yang Q, Yima AP, He GW. The significance of endothelium-derived hyperpolarizing factor in the human circulation. Curr Vasc Pharmacol 2007;5: 85-92.
58. Spector AA, Norris AW. Action of epoxyeicosatrienoic acids on cellular function. Am J Cell Physiol 2007;292:996-1012.
59. Archer SL, Gragasin FS, Wu X, Wang S, McMurtry S, Kim DH et al. Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK(Ca) channels. Circulation 2003;107: 769-776.
60. Urakami-Harasawa L, Shimokawa H, Nakashima M, Egashira K, Takeshita A. Importance of endothelium-derived hyperpolarizing factor in human arteries. J Clin Invest 1997;100:2793-2799.
61. Eichhorn B, Dobrev D. Vascular large conductance calcium-activated potassium channels: Functional role and therapeutic potential. Naunyn Schmiedebergs Arch Pharmacol 2007;376:145-155.
62. Ca) channels of vascular smooth muscle cells. Circulation 2007;116:2435-2443.